The CRISPR system is a revolutionary genome editing tool that has the potential to
revolutionize the field of cancer research and therapy. The ability to precisely target and edit …

Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

In October 2018 a large number of international experts with complementary expertise came
together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI) …

Current antiviral therapies, such as pegylated interferon-α and nucleos (t) ide analogues,
effectively improve the quality of life of patients with chronic hepatitis B. However, they can …

Chronic hepatitis B virus (HBV) infection is one of the high-risk factors for human HCC.
Despite the integration of virus DNA and the oncoprotein HBx, chronic necroinflammation …

Hepatitis B virus (HBV) infection remains a major public health concern worldwide with
about 257 million individuals chronically infected. Current therapies can effectively control …

Fewer than 1% of chronic hepatitis B virus infections per year are cured with antiviral
treatment. This creates a need for long-term treatment, which poses challenges for patients …

With a yearly death toll of 880,000, hepatitis B virus (HBV) remains a major health problem
worldwide, despite an effective prophylactic vaccine and well-tolerated, effective antivirals …

Multiple new therapeutic approaches are currently being developed to achieve sustained,
off-treatment suppression of HBV, a persistent hepatotropic infection that kills~ 2,000 people …

Hepatitis B virus (HBV) persists by depositing a covalently closed circular DNA (cccDNA) in
the nucleus of infected cells that cannot be targeted by available antivirals. Interferons can …